Navigation Links
Sanofi and Regeneron's Dupilumab Named "Clinical Advance of the Year" by Scrip Intelligence
Date:11/25/2013

PARIS and TARRYTOWN, N.Y., Nov. 25, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 2a study of dupilumab in asthma was named "Clinical Advance of the Year" by Scrip Intelligence at the 9th annual Scrip Awards. The award was announced last week by Scrip, a leading pharmaceutical industry publication.

Dupilumab is a fully-human monoclonal antibody that is being developed by Regeneron and Sanofi for the treatment of asthma, atopic dermatitis, and nasal polyposis.

George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories, said, "We appreciate the recognition by Scrip that dupilumab is one of the most exciting emerging clinical candidates in the industry. We feel that this award is additional validation of the overall depth and productivity of our R&D team and the powerful VelociSuite® technologies they employ, which have delivered dupilumab and several other investigational therapeutic opportunities." 

"On behalf of all of the men and women within our organizations working diligently to develop this investigational treatment, we are truly honored by this award," said Elias Zerhouni, M.D., President Global R&D, Sanofi. "The ultimate recognition for their innovative research, at the end of the day, is when we are able to deliver improved solutions to patients." 

Award winners were selected by a 15-member panel of leading pharmaceutical industry executives, consultants, and researchers. More information about the panel is available at: 

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Sanofi Pasteur, the vaccines division of Sanofi ... that the first lots of Fluzone ® (Influenza Vaccine) ... by the U.S. Food and Drug Administration (FDA) for distribution. ... first of at least 65 million doses of seasonal influenza ... U.S. health care providers and pharmacies in August. ...
(Date:7/22/2014)... AVIV, Israel , July 22, 2014 ... a clinical-stage biopharmaceutical company focused on the development and ... of liver diseases and cholesterol gallstones, announced today that ... cleared Galmed,s Investigational New Drug, or IND, application.  Such ... its product candidate, aramchol, in the United ...
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., ... a world-wide, exclusive license agreement with the Icahn School ... ( Mount Sinai ) to utilize its ... Bryostatin-1 in the treatment of Niemann-Pick Type C Disease ... afflicted with Alzheimer-like symptoms. The license also covers other ...
Breaking Medicine Technology:Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 2Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
(Date:7/22/2014)... undergoing a minimally invasive hysterectomy using electric power morcellation, ... at the time of the procedure, according to a ... concern that this procedure, in which the uterus is ... of undetected malignancies. , Despite the commercial availability of ... the prevalence of malignancy at the time of electric ...
(Date:7/22/2014)... Marc, Ph.D., director of research at the University of ... by the International Society of Eye Research (ISER) as ... 2014 Paul Kayser International Award in Retina Research., The ... has made a significant contribution to the understanding of ... this week at the ISER Biennial Meeting in San ...
(Date:7/22/2014)... -- The American Society of Hematology (ASH) will present ... Award for Lifetime Achievement in Hematology, to Kanti R. ... (LIJ) School of Medicine for his 50-year career combining ... mentoring, and exceptional patient care. , The Wallace ... bestowed on an individual who has been a vital ...
(Date:7/22/2014)... As reported on July 17, 2014 by ... name her favorite beauty products, “ Botox , that’s pretty ... “ Botox has changed my life” by halving the ... for her various, daily appearances. “Suddenly my eyelids are ... goo.gl/shmTQM). , “I think that Kelly Ripa’s response to the ...
(Date:7/22/2014)... Autoimmune disorders may share certain pathogenic mechanisms with cancer, ... (GW) researcher Linda Kusner, Ph.D. , published in ... paradigm shifting work shows that the very same inhibitors ... expressed in cells that produce autoimmune diseases. Henry ... at the GW School of Medicine and Health Sciences ...
Breaking Medicine News(10 mins):Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2
... -- New research finds that compared to mammograms, MRI screenings ... the likelihood that high-risk, underserved women who were specially targeted ... big catch. Researchers were able to reduce the cost of ... the usual $3,500 -- thanks to a grant. As a ...
... Ohio People living in poor neighborhoods are at ... hospital than are people who live in wealthier neighborhoods, ... neighborhoods of differing socioeconomic status and out-of-hospital deaths caused ... 1992 and 2002. In each community, and among whites ...
... Industries LLC announced today the opening of a new expanded ... Ltd. The new facility will double the production capacity ... immune support ingredient. , "We are proud to announce the ... the increasing demand from around the world," said Ken-ichi Kosuna, ...
... the Mining Microbial Genomes for Novel Antibiotics research theme ... a recipient of the 2011 National Institutes of Health ... from some of the nation,s most promising new scientists. ... of five years, supports young investigators who have proposed ...
... Interventional Radiology Foundation,s Discovery Campaign, which seeks to further ... of discovery, announced a major corporate pledge to that ... St. Jude Medical, has pledged $100,000 and is a ... Medical Foundation strengthens SIR Foundation,s Discovery Campaign as it ...
... fertility-awareness based method of family planning developed by researchers ... Center so effectively meets the needs of users that they ... study finds that women who follow the Standard Days Method, ... it effectively. Results of the large, multi-country study of 1659 ...
Cached Medicine News:Health News:MRI Can Spot Breast Cancer in High-Risk Women: Study 2Health News:Living in poor neighborhood a risk factor for out-of-hospital cardiac death 2Health News:Living in poor neighborhood a risk factor for out-of-hospital cardiac death 3Health News:Society of Interventional Radiology Foundation accepts St. Jude Medical Foundation gift 2Health News:Long-term effectiveness of new family planning method shown in study 2
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
Inquire...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: